Ushering in a new era of cancer care

Fuzionaire Theranostics’ pipeline includes combinations of therapeutics and PET imaging diagnostics.

We are developing complementary drug pairings to image and treat cancer. Our HetSiFA® platform enables such drug pairings, which target the same marker or receptor expressed on a tumor, to be identical chemical twins that distribute the same way in patients.

Discovery
Lead Optimization
First-In-Patient
Clinical Phase I-III

Proof of concept (target SSTR)

Discovery
Lead Optimization
First-In-Patient
Clinical Phase I-III
18F PET
companion
End PoC study
FTX-TATEs are analogs to FDA-approved 177Lu-DOTA-TATE with the added benefit that the 18F PET companion and the 177Lu therapeutic are identical chemical twins. Commercial-scale manufacturing of several 18F-FTX-TATEs was implemented at four radiopharmacies. PET imaging and BioD in rodents confirmed stability and favorable biodistribution properties. The FTX-TATE proof-of-concept study was successful and is concluded.

Prostate cancer (target GRPR)

Discovery
Lead Optimization
First-In-Patient
Clinical Phase I-III
18F / 177Lu theranostic pair
Our first development program aims to improve the theranostic care of patients with metastatic prostate cancer (mPCa). Recent advances in nuclear medicine have improved and prolonged lives by targeting the prostate-specific membrane antigen (PSMA), but this approach does not benefit some patients. Our chemically identical 18F / 177Lu theranostic pairs target the gastrin-releasing peptide receptor (GRPR) in mPCa to complement available PSMA treatments.

Lung cancer (target SSTR)

Discovery
Lead Optimization
First-In-Patient
Clinical Phase I-III
18F / 177Lu
theranostic pair
By leveraging somatostatin receptor type 2 (SSTR2) antagonists, we target malignancies of neuroendocrine origin with low SSTR2 expression. With this program, we seek to address unmet but critical clinical needs in certain lung and, as a next step, breast cancers.

Prostate cancer (target GRPR/PSMA)

Discovery
Lead Optimization
First-In-Patient
Clinical Phase I-III
18F / 177Lu
theranostic pair
With our program developing a dual-targeting theranostic for PSMA- or GRPR-positive mPCa, we aim to reach mPCa patients irrespective of the underlying tumor biology.